Also published in ncbi.nlm.nih.gov:
Characterization of Transfusion-Derived Iron Deposition in Childhood Cancer Survivors.
x hide permanently

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

ncbi.nlm.nih.gov

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

Oncoimmunology. 2017;6(11):e1358331

Authors: Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV

Mentions: Antibody